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The PIM proteins, which were initially discovered as proviral insertion sites in Moloney-
murine leukemia virus infection, are a family of highly homologous serine/threonine kinases
that have been reported to be overexpressed in hematological malignancies and solid
tumors. The PIM proteins have also been associated with metastasis and overall treat-
ment responses and implicated in the regulation of apoptosis, metabolism, the cell cycle,
and homing and migration, which makes these proteins interesting targets for anti-cancer
drug discovery. The use of retroviral insertional mutagenesis and refined approaches such
as complementation tagging has allowed the identification of myc, pim, and a third group
of genes (including bmi1 and gfi1) as complementing genes in lymphomagenesis. More-
over, mouse modeling of human cancer has provided an understanding of the molecular
pathways that are involved in tumor initiation and progression at the physiological level. In
particular, genetically modified mice have allowed researchers to further elucidate the role
of each of the Pim isoforms in various tumor types. PIM kinases have been identified as
weak oncogenes because experimental overexpression in lymphoid tissue, prostate, and
liver induces tumors at a relatively low incidence and with a long latency. However, very
strong synergistic tumorigenicity between Pim1/2 and c-Myc and other oncogenes has
been observed in lymphoid tissues. Mouse models have also been used to study whether
the inhibition of specific PIM isoforms is required to prevent carcinogen-induced sarcomas,
indicating that the absence of Pim2 and Pim3 greatly reduces sarcoma growth and bone
invasion; the extent of this effect is similar to that observed in the absence of all three
isoforms. This review will summarize some of the animal models that have been used to
understand the isoform-specific contribution of PIM kinases to tumorigenesis.
Keywords: Pim kinases, tumors, proviral tagging, transgenics, knock-out, carcinogens
Pim1 AS A PROVIRAL INTEGRATION SITE FOR MURINE
LEUKEMIA VIRUSES
The proviral insertion site in Moloney-murine leukemia virus
(PIM) proteins are a family of short-lived serine/threonine kinases
that are highly conserved in multicellular organisms throughout
evolution. The PIM family consists of three members,PIM1,PIM2,
and PIM3. These kinases are highly homologous at the amino
acid level (1) but differ partially in their tissue distribution (2).
The PIM kinases have unique structural properties and are char-
acterized by constitutive serine/threonine activity that does not
depend on post-translational modifications for activation. PIM
kinase activity supports the growth and survival of tumor cells
in vitro and in vivo through the modification of an increasing num-
ber of shared and isoform-specific substrates, including c-myc and
Histone H3, which drive transcription; eukaryotic elongation fac-
tor 4E-BP-1, which regulates translation; and Bad, which activates
cell survival. Furthermore, cell cycle protein activation by PIM
kinases is involved in proliferation, and PIM kinases also mediate
the control of energy metabolism through the regulation of AMPK
activity [reviewed in Ref. (3, 4)].
In 1984, Cuypers and co-workers identified pim1 by cloning
the retroviral integration sites in Moloney-murine leukemia virus
(M-MuLV)-induced lymphomas. M-MuLV is a slow-transforming
oncogenic retrovirus that produces mono- or oligoclonal tumors
with a latency of several months; these tumors are usually induced
by the activation or interruption of cellular genes via proviral
integration.
The pim1 gene was identified as a common insertion site in 50%
of T-cell lymphomas that were induced by M-MuLV or AKR-MCF
247 virus (5). Proviral insertion also occurred with a frequency of
45% in the vicinity of c-myc, and an analysis of transplanted lym-
phomas with insertions in the c-myc and pim1 loci revealed that
primary lymphomas were poly- or monoclonal tumors, empha-
sizing the potency of cooperation between these two genes in
driving tumor progression (6–8). Integrations into the pim1 locus
(mouse chromosome 17, which corresponds to human 6p21) lead
to increased mRNA production, increased levels of wild-type pro-
tein, and the development of T- and B-cell lymphomas (5, 8–10).
Proviral insertions (in the sense direction) into the 3′-terminal
exon of the pim1 gene result in the removal of the 3′ UTR, which is
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responsible for reduced mRNA stability. Therefore, the loss of this
region by proviral insertion results in increased Pim1 expression
levels.
Integrations of Moloney-murine leukemia virus into the pim2
locus occur at a lower frequency than integrations into the pim1
locus (8 versus 20%), but this frequency is increased in Pim1 het-
erozygous (10%) and homozygous (25%) knock-out (KO) mice
(11). Integration into the pim2 locus leads to enhanced mRNA
production and promotes T- and B-cell lymphomas.
Several mouse strains have been used to study the proviral inte-
gration of M-MuLV; most of these studies have been carried out
in the BALB/c and C57BL strains, but pim1 rearrangements were
also observed in two T-cell lymphomas, one from an HRS/J mouse
and one from a C58/J mouse. Both rearrangements appeared to
result from ecotopic viral integration. Both proviruses were local-
ized to the 3′ untranslated sequences of the pim1 gene and were
oriented in the same transcriptional direction as pim1 (12), lead-
ing to the cleavage of the transcript at the polyadenylation site
of the 5′ LTR. This premature polyadenylation may result in the
removal of destabilizing sequences and thereby to the production
of transcripts with increased stability (13). In addition to pim1,
similar insertions into the 3′ UTR have been described for pim2
and N-myc.
The inoculation of newborn BALB/c or C57BL1O mice with
M-MuLV revealed insertions near the c-myc, pim1, or pim2 genes
in the primary lymphomas. After transplantation of the primary
tumors, a significant enrichment in the frequency of insertions
near pim2 was observed; this frequency increased from 10% to
over 50% in the transplanted tumors compared to the primary
tumors (14).
Moreover, other viruses have also been shown to integrate into
the pim1 locus, but with a lower frequency. Indeed, the integration
of the Friend murine leukemia virus (F-MuLV) into the pim1 locus
was reported to induce erythroleukemia, and integrations into the
c-myc and pim1 loci have been described in T-lymphoid leukemias
(15). Rearrangements of these two genes are often associated with
p53 gene alterations within the same tumor.
It has been demonstrated that a bcr-abl retrovirus that is
pseudotyped with the Moloney helper virus (bcr-abl/M) can
induce lymphoma in the thymus, although with a prolonged
latency period compared to the v-abl-carrying virus, A-MuLV,
which has not been shown to integrate into known protoonco-
genes. Because of its long latency period, it was assumed that, if
bcr-abl-induced thymomagenesis was affected by retroviral inser-
tion, proviral integration into cooperating loci should be detected
(16). Indeed, the bcr-abl-induced tumors displayed recurring inte-
gration into c-myc, pim1, and Mlvi1, although at lower frequency
than was reported for M-MuLV-induced tumors. Surprisingly,
independent thymomas that were clearly of T-cell origin showed
proviral insertion within the Ahi1 region, which was previously
thought to occur exclusively in A-MuLV/M-induced pre-B-cell
lymphomas.
The Graffi murine leukemia virus is a non-defective retrovirus
that induces granulocytic leukemia in BALB/c and NFS mice. To
identify genes that are involved in Graffi MuLV-induced gran-
ulocytic leukemia, genetic alterations that had been previously
described for other MuLV-induced leukemias were examined.
Three percent of tumors generated by the intraperitoneal inocula-
tion of newborn NFS and BALB/c mice with Graffi MuLV showed
rearrangements in c-myc and pim1, indicating that cooperation
between c-myc and pim-1 activation may also play a role in myeloid
leukemogenesis (17).
In summary, pim1 is a very common insertion site in T-cell lym-
phomas that are induced by M-MLuV infection in different mouse
strains. In contrast, in B-cell lymphomas that are induced by M-
MLuV or other lymphoid diseases induced by different viruses,
the frequency of insertions at pim1 is greatly reduced (Table 1).
TRANSGENIC Pim MOUSE MODELS TO STUDY ONCOGENIC
COOPERATION
The manipulation of the mouse genome can be used to model the
somatic mutations that are found in naturally occurring human
cancers; the aim of these studies is to establish their etiological sig-
nificance and determine the mechanisms by which they predispose
to malignancy (20).
In particular, transgenic mouse models have been developed in
order to address the oncogenic potential of Pim kinases. In most
of these models, only pim1 expression has been genetically altered,
but there are also a few studies in which the functions of pim1
homologs were evaluated using specific transgenic models.
van Lohuizen and co-workers generated an Eµ-pim1 transgenic
strain that contains a duplicated immunoglobulin heavy enhancer
(21) upstream of the pim1 promoter and a single murine leukemia
virus (MuLV) long terminal repeat within the 3′ untranslated
region. The Eµ enhancer achieved a high level of transcription,
and the pim1 transgene was overexpressed in lymphoid tissues
at similar levels in both T- and B-cells. However, only 5–10% of
these mice developed T-cell lymphoma with a latency period of
240 days (22).
Eµ-Pim1 mice have a very low rate of developing T-cell lym-
phomas with a long latency, but infection with M-MuLV virus dra-
matically increases the incidence of lymphoma and shortens the
latency of T-cell lymphoma development (56–64 versus 154 days)
(22). The activation of either c-myc or N-myc was involved in every
analyzed tumor, emphasizing the importance of the pim/myc col-
laboration in tumor development (22–24). Additionally, retroviral
insertions in the ice1/gfi1/pal1/evi5 locus were observed in nearly
80% of the lymphomas (25).
As mentioned above, the transgene in Eµ-pim1 transgenic mice
is expressed in both B- and T-cells. This pattern contrasts with that
of Eµ-c-myc transgenic mice, which develop spontaneous B-cell
lymphoma with a high incidence rate. Moreover, Eµ-pim1 trans-
genic mice do not display anomalies in the bone marrow, whereas
the bone marrow of Eµ-c-myc transgenic mice was profoundly
abnormal, showing enhanced proliferation of premature B-cells
(26, 27). This apparent lack of increased hematopoietic cell prolif-
eration in Eµ-pim1 transgenic mice could indicate that pim1 alone
cannot cause massive cell proliferation in any of the hematopoi-
etic compartments in which it is expressed (22). Likewise, the
retroviral infection of transgenic Eµ-myc mice led to the integra-
tion of the provirus in the pim1 locus in 35% of tumors (10).
Although Eµ-c-myc transgenic mice already displayed a high inci-
dence of B-cell lymphomas with a short latency, the development
of tumors was enhanced after retroviral infection. These results
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Table 1 | Pim1 as a proviral integration site.
Virus Mouse strain Locus of insertion (frequency %) Tumor type
M-MuLV BALB/c, C57BL 3′ Region of pim1 (50%) Early T-cell lymphoma (5)
M-MuLV BALB/c, C57BL 3′ Region of pim1 (50%); 3′ region of c-myc (45%) Early T-cell lymphoma (6)
M-MuLV BALB/c 3′ and 5′ Regions of pim1 (50% early lymphomas,
7% late lymphomas)
Early and late T-cell
lymphoma (8)
M-MuLV BALB/c, C57BL Oligoclonal and monoclonal in c-myc and pim1 Early T-cell lymphoma (7)
M-MuLV AKXD 3′ Region of pim1; 3′ region of c-myc T- and B-cell lymphomas (9)
Ecotropic virus HRS/J, C58/J 3′ Region of pim1 (11%) T-cell lymphoma (12)
Mo+, Mo+PYwt, Mo+PyF441
M-MuLVs
NIH Swiss Mo+pim1 (33%), Mo+PYwt pim1 (13.3%), Mo+
PyF441 no insertion
Lymphoblastic lymphoma
(18)
M-MuLV BALB/c, C57BL, B6 nude (nu/nu) No insertion at the pim1 locus B-cell lymphomas (19)
Transplanted lymphomas induced
by M-MuLV
BALB/c, C57BL10 Retain integration in c-myc, pim-1 enrichment of
pim-2 insertion from 10% to over 50%
T-cell lymphoma (14)
M-MuLV BALB/c, C57BL10 pim2 and pim1 (21%); 10% of cells affected T-cell lymphoma (14)
Friend helper leukemia virus
(F-MuLV)
ICFW p53 (35%), p53 and pim-1 (24%), p53 and c-myc
(6%), c-myc (12%)
Erythroleukemia (15)
M-MuLV and bcr-abl/M BALB/c M-MuLV: pim1 (33%); bcr-abl/M: pim1 (14%) Thymoma (16)
Graffi murine leukemia viruses Balb/c and NFS pim1 (3%) Myeloblastic leukemia (17)
support the findings that the myc and pim1 genes collaborate in
lymphomagenesis.
The cooperation between the myc and pim genes was ulti-
mately proven by experiments using Eµ-c-myc;Eµ-pim1 and
Eµ-c-myc;Eµ-pim2 double-transgenic mice, in which pre-B-cell
leukemia presented around birth (28, 29). By crossing heterozy-
gous animals of both genotypes, it was observed that Eµ-c-
myc;Eµ-pim1 mice expressing high levels of c-myc were not viable,
whereas Eµ-c-myc;Eµ-pim1 mice expressing low levels of c-myc
were viable and showed a low tumor incidence. To gain insight
into the cause of the perinatal lethality of the double-transgenic
mice that expressed the indicated transgenes at high levels, 17–
19-day-old fetuses were collected and examined histologically.
Major changes were observed in the livers and spleens of these
fetuses, and immunochemistry revealed that the expanded cell
population in the fetuses carried the B-cell-specific cell surface
marker B220, indicating that these cells represent pre-B-cells. The
transplantation of these leukemic cells into nude mice resulted
in tumor outgrowth within 54 days in 80% of the animals. The
authors concluded that upon transplantation into recipient mice,
the embryo-derived double-transgenic leukemic cells frequently
seemed to be derived from different ancestor cells; these ancestor
cells progressed to highly malignant monoclonal tumors, indicat-
ing that additional selective forces may act on these cells, resulting
in the outgrowth of adapted subclones of tumor cells (28).
Breuer et al. developed another pim1 transgenic mouse line,
H2K-pim1. This construct was derived from the Eµ-pim1 con-
struct, in which the pim1 promoter region was replaced with
that of the H2K promoter. Although 10% of Eµ-pim1 transgenic
mice developed tumors within 240 days, H2K-pim1 mice did not
develop tumors spontaneously, and the administration of chem-
ical carcinogens such as N -ethyl-N -nitrosourea was needed to
increase the incidence of lymphomas; this model will be described
below (23).
Berns and co-workers also used proviral tagging to identify
collaborating oncogenes and genes that contribute to tumor pro-
gression. Four transgenic lines (TDK-pim1, Eµ-c-myc, H2K-myc,
and Eµ-Bmi1) were used in this study, and activation by retrovi-
ral tagging allowed the authors to assess the collaborative roles of
c-myc, N-myc, pim1, pim2, Bmi1, and Gfi1 (30). Pim1 transgenic
mice were generated using a TDK expression cassette, in which
the immunoglobulin heavy chain enhancer is combined with the
pim1 promoter and the M-MLuV terminal repeat. The only differ-
ence from the previously described Eµ-pim1 mouse model is the
FVB/N strain background. As was described before, the activation
of c-myc, N-myc, and Gfi1 was observed in these TDK-pim1 trans-
genic mice, whereas the activation of pim1, pim2, c-myc, and N-myc
was predominant in the Bmi1 transgenic mice (30). Furthermore,
the expression patterns of the transgenes in these mouse lines
promoted different types of tumors, yielding almost exclusively
B-cell lymphomas in the Eµ-c-myc transgenic mice, whereas the
H2K-myc transgenic mice developed mainly T-cell lymphomas.
In contrast, the TDK-Bmi1 mice showed predisposition to both B-
and T-cell lymphomas.
More recently, An et al. generated another transgenic mouse
overexpressing human pim1 using vav hematopoietic regula-
tory elements and SV40 sequences (31). Pim-Tx mice showed
enhanced hematopoiesis characterized by an increased number
of hematopoietic stem/progenitor cells (Lin-Sca-1+ c-Kit+) and
cobblestone area-forming cells, along with a higher degree of BrdU
incorporation in long-term hematopoietic stem cell populations
and a greater ability to reconstitute lethally irradiated mice.
In addition to hematopoietic tissues, the oncogenic role of Pim1
and its synergy with c-myc in tumorigenesis have also been studied
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in prostatic epithelium by Wang and co-workers. In this case,
lentiviral constructs that coexpressed pim1, a kinase-dead (K67M)
mutant pim1, human c-myc, or c-mycCS62D were generated and
used to infect prostate cell suspensions isolated from C57BL/6
mice singly or in combination (c-myc/pim-1 or c-myc/K67M)
(32). After infection, these cells were combined with rat urogenital
sinus mesenchyme and grafted under the renal capsules of SCID
mice to regenerate prostates. The results indicated that pim1 was
also weakly oncogenic in the prostate environment, but it coop-
erated dramatically with c-myc to induce prostate cancer within
42 days, generating large hemorrhagic tumors, while the control,
pim1, K67M, or c-myc or c-myc/K67M grafts were small and did
not differ significantly in their sizes. This finding was reinforced by
the observed increase in the active serine-62 (S62)-phosphorylated
form of c-myc in the c-myc/pim1 tumors. However, grafts express-
ing the phosphomimetic c-myc CS62D mutant had higher rates
of proliferation than grafts expressing the wild-type c-myc but did
not form tumors like the c-myc/pim1 grafts, indicating that the
cooperation between pim1 and c-myc in vivo involves mechanisms
other than the enhancement of c-myc activity by S62 phosphory-
lation. In contrast to pim1 grafts, all of the c-myc and c-myc/K67M
grafts showed multiple foci of high-grade prostate intraepithelial
neoplasia (PIN), a putative precursor lesion for prostate carci-
noma, but none of them showed evidence of invasive cancer after
42 days (32).
To evaluate pim1 inhibition as a therapeutic target for prostate
cancer, particularly for myc-expressing tumors, the same authors
examined the molecular consequences of pim1 and myc over-
expression in the prostate and the effects of depleting pim1 in
prostate carcinoma cells with high levels of myc. For this purpose,
the mouse prostate tissue (MPT) cell line was generated from c-
myc/pim1 prostate tissue recombinant grafts that overexpressed
both oncogenes. To study the effect of pim1 expression, these
cells were infected with an shRNA against mouse pim1 (named
shPim1#1). The knock-down of pim1 did not lead to a compen-
satory increase in pim2 or pim3, and there were no appreciable
changes in the levels of myc protein in MPT cells. However, the
knock-down of pim1 substantially reduced cellular proliferation
and focus-forming ability, which are typical of cancer cells, com-
pared with cells expressing a control shRNA (shControl#1). In
addition, the in vivo tumorigenicity was evaluated by injecting
shPim1#1 or shControl#1 MPT cells subcutaneously into athymic
nude mice. No tumors were observed in the pim1 knock-down
group after 84 days, whereas 60% of the mice in the control group
formed large tumors. A subsequent analysis of the expression of
different kinases in MPT cells showed that, although there were no
consistent changes in Akt signaling, Erk1/2 phosphorylation was
consistently reduced in pim1 knock-down cells compared to the
corresponding control cells (although the stable overexpression of
pim1 in prostate cancer cells did not alter Erk phosphorylation).
In contrast, an examination of pim1-expressing recombinant
prostate grafts in vivo showed evidence of enhanced Erk1/2 phos-
phorylation. Overall, these results indicated that pim1 may not be
sufficient to promote the onset of invasive prostate cancer but sug-
gested that pim1 expression may be necessary for maintaining Erk
signaling and, therefore, prostate cancer cell tumorigenicity (32).
More recently, we generated a conditional Pim1 transgenic
mouse model to assess the contribution of PIM1 to neoplastic ini-
tiation and progression in the prostate epithelium. Human Pim1
was cloned into the pVL-1 vector, and a stop cassette flanked by
LoxP sequences was inserted before the hPim1 cDNA. This con-
struct was injected into embryonic stem cells, and embryos bearing
this construct were transferred into pseudo-pregnant mice. These
animals were crossed with another transgenic mouse model that
expressed Cre recombinase under the control of the PSA promoter
(PSA61-cre); this allowed CRE expression and the subsequent
transcription of pim1 transgene primarily in prostate tissue and,
upon hormone treatment, in bladder tissue. Using these pim1;
PSA61-cre mice, the effect of pim1 overexpression was explored
in three different settings: after hormone treatment, during aging,
and in combination with the absence of one pten allele. We found
that pim1 overexpression moderately increased the severity of
mouse prostate intraepithelial neoplasia (mPIN) in all three set-
tings. Furthermore, Pim1 overexpression in combination with
hormone treatment increased inflammation in the surrounding
target tissues, leading to pyelonephritis in the transgenic ani-
mals. The increased inflammation observed in the pim1 transgenic
mice after hormone treatment may be due to a positive feedback
loop between hormone treatment and pim1 transgene expression
because only these mice developed inflammation and subsequent
pyelonephritis. An analysis of the senescence induced in these pro-
static lesions showed that the lesions generated in the presence of
inflammation exhibited different behavior than those that were
induced in the absence of inflammation. In the presence of inflam-
mation, high-grade prostate preneoplastic lesions (mPIN grades
III and IV) did not show any senescence markers and demon-
strated high levels of Ki67 staining. However, untreated animals
without inflammation expressed senescence markers and had low
levels of Ki67 staining in similar high-grade lesions. These data
suggested that pim1 may contribute to progression rather than
initiation in prostate neoplasia, indicating that pim1 plays a role
in promoting prostate tumorigenesis in vivo, although it displayed
distinct oncogenic activities depending on the disease stage (33).
After prolonged hormone treatment, pim1 was also expressed in
the urothelial epithelium, inducing urothelial hyperplasia in the
bladder and hyperplasia of the urethra in mice overexpressing
pim1 alone or with the simultaneous loss of one pten allele. This
hyperplasia may lead to light occlusion of the bladder and urethra
because 50% of the animals overexpressing the pim1 transgene
developed pyelonephritis and needed to be sacrificed. These data
suggested that an increase in pim1 expression may contribute to
the progression of urothelial neoplasia, rather than its initiation,
and that urothelial hyperplasia may be an important factor in the
development of pyelonephritis (34).
In addition to these pim-1 transgenic mouse models, there are a
few studies in which the pim2 and pim3 isoforms were genetically
modified in order to characterize the function of these proteins.
There is evidence from M-MuLV viral tagging experiments sug-
gesting that the oncogenic behavior of Pim2 is similar to that
of Pim1; for example, both genes are highly expressed in mito-
genically stimulated hematopoietic cells, and their transcription
is induced in response to the same cytokines. To follow up on
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these data, Allen and co-workers developed an Eµ-pim2 trans-
genic mouse model. In this mouse model, the overexpression of a
pim2 transgene in lymphoid cells predisposed mice to T-cell lym-
phomas that were similar to those promoted by pim1 transgenes.
In particular,40% of the Eµ-pim2 transgenic animals developed T-
cell lymphomas within 1 year of age, and these lymphomas showed
similar histological characteristics to those observed in Eµ-pim1
mice. Moreover, a strong collaboration between the Eµ-pim2 and
Eµ-c-myc transgenes was observed; pre-B-cell leukemia developed
in neonatal bi-transgenic animals (29). These animals developed
severe leukemia and died before 28 days of age. At birth, their
appearance was normal, but their growth was noticeably retarded
thereafter, reaching only half the weight of their litter mates. A
consistent leukemic phenotype was observed in these animals,
with large undifferentiated lymphoblastoid cells infiltrating most
tissues. These results confirmed that pim2 was an oncogene that
potently collaborated with c-myc, even when it was only modestly
overexpressed and that the resulting tumors were similar to those
obtained with the pim1 transgene (29).
Wu et al. addressed the role of Pim3 in the progression of hepa-
tocellular carcinoma (HCC) by generating a transgenic mouse
that selectively overexpressed human PIM3 in the liver (35). This
line was developed by cloning the full-length human Pim3 cDNA
downstream of the mouse albumin enhancer/promoter gene (36)
and introducing this construct into fertilized oocytes of C57BL/6
mice following a standard transgenic technique. When these pim3
transgenic mouse-derived hepatocytes were analyzed, Bad was
found to be constitutively phosphorylated at Ser112 (indicating
that the overexpressed PIM3 was functional) and the levels of
cyclin D1 and proliferating cell nuclear antigen were increased
relative to wild-type mice. Moreover, a cell cycle analysis of
hepatocytes isolated from Pim3 transgenic mice indicated that
the proportion of cells in the G2/M phase was significantly
increased, suggesting that PIM3 overexpression could accelerate
the cell cycle progression of hepatocytes. However, the devel-
opment of spontaneous HCC was not observed in liver-specific
Pim3 transgenic mice (35). Nevertheless, the administration of
diethylnitrosamine (DEN), a potent hepatocarcinogen, induced a
higher proliferation rate in pim3 transgenic mouse cells. While
HCC was detected in 40% of wild-type mice 10 months after this
treatment, a higher frequency (80%) of Pim3 transgenic mice
developed HCC, and those mice had a heavier burden. These
observations indicated that PIM3 alone could not cause the devel-
opment of HCC, but could accelerate its development induced by
a hepatocarcinogen.
All of these described models are summarized in Table 2.
Pim KNOCK-OUT MICE
To further determine the role of Pim1 in tumorigenesis, Pim KO
mice have been widely used. In general, none of the individual
Pim-KO models (with depletion of one of the three Pim kinases)
developed a notable phenotype. These mice do not display any
overt abnormalities; all of the major organs were within the nor-
mal range of size and structure as indicated by morphological and
histological analyses. The behavior and body weight of the animals
were also normal for all genotypes (homozygous knock-outs and
heterozygous littermates) (37).
Over the years,only mild hematopoietic impairments have been
detected in the single Pim-KO models, which is surprising given
the high evolutionary conservation of these kinases.
Table 2 | Mouse models overexpressing Pim proteins.
Mouse model Expression of transgene Phenotype
Eµ-pim1 B- and T-cells Enlargement of the spleen
Monoclonal T-cell lymphoma with high expression of c-myc; 10% penetrance, 240 weeks
latency (22–24)
H2K-pim1 B- and T-cells No spontaneous tumors (23)
Pim1-Tx Lymphoid lineage: higher
expression in B lymphoid
cells than in myeloid cells
Enhanced hematopoiesis, higher BrdU incorporation in long-term HSC populations, and
greater ability to reconstitute lethally irradiated mice
Acute lymphoblastic leukemia/lymphoma; 10% penetrance, 20–62 weeks latency (31)
pim1; PSA61-Cre Prostate and bladder
epithelium
100% of 10-month-old mice developed low-grade mPIN lesions
The incidence of low-grade and high-grade mPIN lesions increases after two rounds of
hormone treatment. All (100%) of the mice developed mPIN lesions at 24 weeks of age,
with a 10% incidence of high-grade mPIN and in situ carcinoma (33)
All (100%) of the mice developed high-grade bladder and urothelial hyperplasia after two
rounds of hormone treatment, inducing pyelonephritis (34)
Eµ-pim2 B- and T-cells T-cell lymphoma in 40% of the mice after 1 year (29)
alb-pim3 Hepatocytes No tumors after 1 year (35)
Tissue recombination
model coupled with
lentiviral-mediated gene
transfer
Prostate cells from
6-week-old C57BL/6 mice
infected with lentivirus
Pim1 is weakly oncogenic in naïve adult mouse prostatic epithelium. However, it
cooperates dramatically with c-myc to induce high-grade prostatic cancer with NE
differentiation
100% penetrance in 6 weeks (32)
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In 1993, two studies involving Pim1-KO mice were published.
Laird and co-workers generated mice that carried a pim1 allele
incapable of producing a functional Pim1 protein. These mice
were generated by deleting the promoter sequences, transcrip-
tion and translation initiation sites and a large segment of the
coding region including the conserved lysine residue of the ATP
binding site of the protein kinase domain (38). The resulting
Pim1-deficient mice are ostensibly normal, healthy, and fertile.
The only reported phenotype was a significantly smaller erythro-
cyte mean cell volume (MCV) compared to wild-type littermates
(37). Because the peripheral blood concentration of erythrocytes
was not increased in Pim1-deficient mice, hemoglobin levels were
reduced. Further rescue experiments using a Pim1 transgene with
an expression level similar to the endogenous pim1 gene showed
that MCV levels could be restored to just below the levels of
wild-type littermates (37).
Another study, published by Domen and co-workers, analyzed
the early B lymphoid compartment from both Pim1 null mutant
and Eµ-pim1 transgenic mice. These null mutant mice also lacked
an obvious phenotype but showed an impaired response to inter-
leukin 7 (IL-7) and steel factor (SF). A comparison of the total
number of bone marrow cells recovered from Pim1 mutants and
their wild-type controls revealed no significant differences. The
level of Pim1 expression appears to be a determining factor in
the ability of these cells to respond to IL-7 and SF. The impaired
response in null mutant mice could be rescued by the introduc-
tion of a functional pim1 transgene. Moreover, the overexpression
of Pim1 facilitated the derivation of primitive lymphoid cell lines
that are dependent on combined stimulation with IL-7 and SF or
insulin-like growth factor 1 (39). However, the absence of Pim1
in null mutant mice did not lead to a total lack of responsiveness
to IL-7 and SF, which indicates that Pim1 is more of a modulator
than a mediator for these factors (39).
The animal model used in the previous study was later exam-
ined by Konietzko and colleagues, who determined Pim kinase
expression after long-term potentiation (LTP) stimulation. In the
brain, Pim1 is induced by plasticity-producing stimulation and
is instrumental in the formation of enduring LTP. Pim1 is also a
determining factor for establishing long-lasting changes in synap-
tic strength (40). Pim1-deficient mice showed normal synaptic
transmission and short-term plasticity. However, they failed to
consolidate enduring LTP, even though Pim2 and Pim3 are con-
stitutively expressed in the hippocampus and Pim3 expression is
similarly induced by synaptic activity (40). This impairment in
LTP consolidation may affect certain forms of long-term mem-
ory because synaptic plasticity appears to play a role in several
physiological and pathological processes of the adult brain such
as learning and memory (41, 42). Overall these findings may indi-
cate that Pim1 plays an important role in regulating the functional
changes that underlie long-term synaptic plasticity (40).
All of the mice that were deficient in only one Pim kinase
(single-KO) displayed mild phenotypes with only slight impair-
ments. However, this is different from animals lacking all three
Pim kinases. Although mice lacking expression of Pim1, Pim2,
and Pim3 [referred to as triple knock-out mice (TKO)] are viable
and fertile, they showed a profound reduction in body size at birth
and throughout postnatal life. This reduction is due to a decrease
in cell number rather than a decrease in cell size (43). Similar to
the Pim1 single-KO mice, TKO mice displayed a decreased MCV
in erythrocytes. They also have a decreased splenic B-cell frac-
tion in addition to other B-cell impairments such as a decrease
in the IL-7-mediated proliferation of late pre-B-cells. In addition,
the in vitro response of distinct hematopoietic cell populations to
growth factors is severely impaired. For example, bone marrow
cells showed an impaired growth response to IL-3. In particu-
lar, the Pim proteins are required for the efficient proliferation of
peripheral T lymphocytes mediated by synergistic T-cell receptor
(TCR) and interleukin-2 signaling (43).
Because PIM kinases are attractive targets for anti-cancer drug
discovery, it is important to further determine the relative con-
tribution of the different isoforms to tumorigenesis in vivo and
to understand how their individual inhibition might affect tumor
growth and the normal physiology of organisms.
Using the TKO mice generated by Mikkers et al., we explored
whether the inhibition of specific isoforms is required to pre-
vent the sarcomas induced by treatment with the carcinogen
3-methylcholanthrene (44). We showed that the absence of Pim2
and Pim3 greatly reduced sarcoma growth and that the extent of
this reduction was similar to that observed in the absence of all
three isoforms. This model of sarcoma generally involves bone
invasion by the tumor cells. The lack of Pim2 and Pim3 reduced
tumor-induced bone invasion by 70%, and this reduction is com-
parable to the reduction of tumor-induced bone invasion in the
absence of all three isoforms (44), although the absence of all three
isoforms is necessary to achieve the maximum effect. These data
concur with data derived from cell assays using mouse embryonic
fibroblasts showing reduced proliferation rates and resistance to
oncogenic transformation.
An et al., using the Pim-TKO mice that were generated
by Mikkers et al., were able to show that hematopoietic stem
cells (HSCs) from Pim1-KO mice had an impaired long-term
hematopoietic repopulating capacity in secondary and compet-
itive transplantations, whereas the data from Pim2 KO and Pim3
KO mice were similar to those from wild-type mice (31). Pim1-
deficient and TKO mice had a lower peripheral blood platelet
count and exhibited erythrocyte hypochromic microcytosis. The
bone marrow cells of Pim1-KO and TKO mice demonstrated
a decreased hematopoietic progenitor colony-forming ability.
Importantly, the bone marrow cells from Pim1-KO and TKO mice
also showed a significantly impaired ability to rescue lethally irra-
diated mice and reconstitute hematopoiesis in primary, secondary,
and competitive transplant models. Furthermore, in vivo BrdU
incorporation in long-term HSCs was reduced in Pim1-deficient
and TKO mice (31, 45). Finally, cultured HSCs from Pim1-KO
mice showed a reduced proliferation rate, as measured by Ki67
staining, and a higher rate of apoptosis via caspase 3 activation
(31). Most interestingly, a genetic survey revealed that several
genes, including Lef-1 and Pax-5, are affected by the deletion of
Pim1 kinase in HSCs, emphasizing the important role of Pim1 in
the function and regulation of HSCs (31).
A summary of the different Pim-KO mice and their phenotypes
is shown in Table 3.
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Table 3 | Mouse models with deletions of the Pim proteins.
Mouse model Phenotype Reference
Pim1− /− Erythrocyte microcytosis. Impaired response to IL7 and SF. HSCs showed impaired long-term hematopoietic
repopulating capacity in secondary and competitive transplantations. Fail to consolidate enduring long-term potentiation
(31, 37, 39,
40)
Pim2− /− HSCs mice behaved normally in a long-term hematopoietic repopulating capacity in secondary and competitive
transplantations
(31)
Pim3− /− HSCs mice behaved normally in a long-term hematopoietic repopulating capacity in secondary and competitive
transplantations
(31)
Pim1− /−;
Pim2− /−;
Pim3− /− (TKO)
TKO mice exhibited reduced body size, a severely impaired in vitro response of distinct hematopoietic cell populations to
growth factors, thrombocytopenia, and hypochromic erythrocytes. HSCs showed impaired long-term hematopoietic
repopulating capacity in secondary and competitive transplantations
(43, 45)
Pim2− /−;
Pim3− /− (DKO)
TKO
Absence of Pim2 and Pim3 greatly reduced the sarcoma growth induced by 3MC, to an extent similar that observed in
the absence of all three isoforms. The lack of Pim2 and Pim3 reduced tumor-induced bone invasion by 70%, which is
comparable to the reduction of tumor-induced bone invasion in the absence of all three isoforms
(44)
COOPERATION BETWEEN OTHER ONCOGENES AND Pim1 BY
PROVIRUS INSERTION OR pim1 OVEREXPRESSION
As has been described before, proviruses in several different tumor
models are integrated into a single tumor cell clone in two or
more different loci. For example, in M-MuLV-infected Eµ-pim1
transgenic mice, lymphomagenesis is accelerated, and retroviral
insertion into c-myc or the N-myc is detected with a high fre-
quency. These data confirm that pim and myc are complementary
genes in lymphomagenesis (22).
Transgenic mice that overexpress the c-myc gene under the
immunoglobulin heavy chain enhancer (Eµ-c-myc mice) develop
B-cell lymphomas at a high frequency (10, 27, 46). The fact that
the tumors are clonal and often appear after an extended latency
period suggests that additional events are necessary for their devel-
opment. To identify genes that synergize with the c-myc transgene,
Eµ-myc mice were infected with M-MuLV shortly after birth. As
anticipated, the pim1 gene was activated by proviral integration
in 35% of the tumors, and sporadic insertions into the pim2 and
the ahi1 loci were detected. In addition to pim1, three other main
proviral integration sites were identified: bmi1, bla1, and pal1 (10,
47). The generation of an Eµ-Bmi1 mouse line confirmed the role
of bmi1 in lymphomagenesis; these mice had perturbed lymphoid
development and were highly susceptible to B- and T-cell lym-
phomagenesis. Proviral tagging in Eµ-Bmi1 transgenic mice was
used to identify genes that cooperate with bmi1 in lymphomagen-
esis (48). The activation of the pim and myc genes was frequently
observed and led to accelerated development of B- and T-cell
lymphomas.
The substitution of Eµ-c-myc with Eµ-N-myc or Eµ-L-myc
also resulted in enhanced lymphomagenesis (49). Complementa-
tion of the Eµ-N-myc and Eµ-L-myc transgenic mice by breed-
ing them with Eµ-pim1 animals led to the more rapid devel-
opment of lymphoid malignancies and a dramatically higher
incidence, but the lineage specificity prescribed by the Eµ-N-
myc and Eµ-L-myc transgenes was maintained (B- and T-cells,
respectively). Eµ-N-myc;Eµ-pim1 bi-transgenic mice had severe
anemia and lymphoma with involvement of all lymphoid organs,
while a profound acceleration of lymphomagenesis was observed
in Eµ-L-myc;Eµ-pim1 bi-transgenic mice. Large immature lym-
phoblasts were detected in blood smears of double-transgenic
animals, demonstrating a high degree of leukemia. In addition, the
different oncogenic potential of the myc genes was revealed by the
average latency period of tumor manifestation; the latency period
was 36 days for Eµ-N-myc:Eµ-pim1 mice and 94 days for Eµ-
L-myc;Eµ-pim1 mice, but Eµ-c-myc;Eµ-pim1 animals developed
pre-B-Cell leukemia prenatally (49).
In 1997, it was shown that the eis-1/pal-1/gfi-1/evi-5 locus
serves as a target for M-MuLV proviral insertions in pre-B-cell
lymphomas in Eµ-myc transgenic mice (20%) and in T-cell lym-
phomas in H2K-myc (75%) and Eµ-pim1 (93%) transgenic mice
(25). This common insertion site had been identified as a region
containing several independent integration clusters: eis1, gfi1,
and evi5. Proviral insertion into the different integration clus-
ters upregulates the transcription of the gfi1 gene, which is located
in the pal-1 locus. Transgenic mice that constitutively expressed
high levels of gfi1 in the T-cell lineage were later generated using
the proximal lck promoter (lck-gfi1). These animals appeared to
have unexpectedly low thymocyte numbers and to be weakly pre-
disposed for lymphomagenesis. However, the coexpression of a
transcriptionally deregulated pim1 gene restored the number of
mature T-cells in the lymph nodes and spleen in double-transgenic
mice. In addition, after a latency period of 114 days, almost all
of the double lck-gfi1; Eµ-pim1 transgenic mice developed T-cell
lymphoma, which demonstrated the potential of gfi1 as a domi-
nant oncogene and its ability to synergize with pim gene. A similar
accelerated rate of lymphoma development was observed when
lck-gfi1 mice were crossed with mice that carried an L-myc gene
that was targeted to be expressed at high levels in T-cells. In this
case, the mean latency period for tumor development was 148 days,
again providing direct evidence for a cooperative effect between
myc and gfi1 (50).
On the other hand, retroviral (M-MuLV) insertion in trans-
genic mice expressing Myc under the T-cell-specific CD2 locus
control region (CD2-myc) led to the identification of the til1
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locus; insertions into til1 result in the increased transcription
of the runx2/cbfa1/aml3/pebp2αA gene (51–53). Runx2 is one
member of the core binding factor family, a set of heterodimeric
regulatory proteins with vital roles in hematopoiesis and osteo-
genesis. It has been reported that T-cell development is per-
turbed when the runx2 oncogene is overexpressed; this change
leads to the development of spontaneous lymphomas at a low
frequency and acts synergistically with myc (54). Retroviral infec-
tion of CD2-runx2 transgenic mice identified c-myc and pim1
as collaborating genes (55). Moreover, insertional mutagenesis
(M-MuLV) of CD2-myc;CD2-runx2 double-transgenic mice also
led to insertions in the pim1 locus (51). To assess the possible
functional redundancy between the runx2 oncogene and known
myc-collaborating genes in T-cell lymphomagenesis, mice overex-
pressing runx2 (CD2-runx2) were crossed with mice carrying the
Pim1 transgene (Eµ-pim1). CD2-runx2; Eµ-pim1 animals dis-
played a significant increase in tumor onset compared to either
CD2-runx2 or Eµ-pim1 littermate controls. At 250 days of age,
66% of the double-transgenic mice succumbed to spontaneous
T-cell lymphoma, whereas only 23% of the CD2-runx2 mice and
none of the Eµ-pim1 mice did. This work demonstrated that in
addition to the strong synergy between runx2 and myc, runx2
seemed to collaborate independently with pim1, demonstrating
that it contributed to T-cell lymphoma development in a unique
manner with a dominant effect on the tumor cell lineage and
phenotype (55).
Retroviral insertion was also used to elucidate the role of
pim1 in large B-cell lymphomas. Mutations and chromosomal
rearrangements involving the bcl6 gene have been found in the
majority of diffuse large B-cell lymphomas in humans (56).
An inducible transgenic mouse model that is doubly transgenic
for the tetracycline-responsive tet-o-bcl6 gene and the tissue-
specific tetracycline-transactivating protein EµSR-tTA has been
constructed to investigate the role of Bcl6 in this type of cancer
in detail (57). By retroviral insertion (MOL4070LTR), pim1 was
identified as the most frequently recurring cooperating gene in this
system, and elevated levels of pim1 mRNA and protein expression
were observed in these neoplasms (B- and T-cell type) (58).
Although the role of pim1 in retrovirus-induced lymphomage-
nesis has been established, the downstream targets of Pim1 that are
involved have been largely unknown. Viral infection of KO mice
can be used to address whether a given gene can contribute to the
development of a certain type of cancer.
In Pim1-KO mice, integration of M-MulV into the pim2 locus,
which occurs in 25% of all integrations, provokes T- and B-cell
lymphoma via enhanced mRNA production (11). A further 28%
of the integrations occurred in the c-myc and N-myc loci of
these mice, and integration into these loci occurred more often
in Pim1 heterozygous KO mice (51%), or in Pim1-wild-type
mice (44%). Taking advantage of the strong interaction between
pim1 and c-myc, a retroviral screening approach was established
to search for the retroviral activation of genes that act down-
stream of or in parallel to pim1. The frequency of integrations
into the pim2 locus was significantly higher in the Eµ-myc-mouse
model and higher in combination with deletions of the pim1
allele. In Eµ-c-myc;Pim1−/− mice, more than 80% of the retro-
virally induced tumors contained a proviral integration into pim2.
Furthermore, Eµ-myc transgenic mice lacking the expression of
pim1 and pim2 have been infected with M-MuLV and analyzed by
a high-throughput genetic screen (59). In addition to the expected
pim3, several other genes could be identified, including the tyrosine
kinase receptor Kit and the cell cycle regulator Ccnd2. Although
the exact roles of these factors in Pim signaling have yet to be
elucidated, the diverse nature of these proteins suggests that Pim
kinases are embedded in a complex network.
The Eµ-transgene system was widely used to search for genes
that cooperate with various oncogenes. The v-abl gene is known to
be implicated in several types of lymphoid neoplasms. Haupt and
co-workers generated Eµ-v-abl 40 transgenic mice and reported
that these animals spontaneously develop plasmacytomas. While
retroviral infection with M-MuLV only moderately accelerated
tumorigenesis, the tumor type was altered: nearly all of the
detected tumors after M-MuLV infection were T-cell lymphomas
(60). Insertions in the c-myc, N-myc, and pim1 loci were observed,
indicating that each of these genes can collaborate with v-abl in
lymphomagenesis. Furthermore, one monoclonal tumor involved
both c-myc and pim1 together with v-abl, suggesting that all three
genes may collaborate.
Shinto et al. also used infection with M-MuLV to investigate
the contribution of additional genes to bcl2-driven tumorigenesis
(61). Eµ-bcl2 transgenic mice sporadically develop B- or T-cell
lymphoma after a long latency period. While M-MuLV mainly
induced mature T-cell lymphomas in wild-type mice, infection
of transgenic mice led to the development of clonal pre-B-, B-,
and mainly immature T-cell lymphoma. Proviral insertion was
detected in the following loci: pim1 (6%), pim2 (23%), and c-myc
(26%). Some tumors showed proviral insertions close both to the
c-myc and pim2 genes.
The clinical outcome of lymphoma was also evaluated by
Wendel et al. after generating double-transgenic mouse models.
In this case, the Eµ-c-myc model of aggressive lymphoma (46)
was adapted to the transplantation approach using retrovirally
transduced hematopoietic progenitor cells (62). This transgenic
construct enabled murine pim2 or constitutively active myristoy-
lated AKT expression in the recipient C57Bl/6 mice. Therefore,
when the animals were monitored for lymphomas, Eµ-myc/pim2-
and Eµ-myc/AKT -expressing tumors had an accelerated disease
onset compared to controls and histopathology and surface mark-
ers that were indistinguishable from those of aggressive pre-B-cell
lymphomas. Hence, Pim2 and AKT activate protein translation
and promote lymphomagenesis in a mouse model of aggres-
sive and indolent lymphoma (63). Moreover, mice developing
Eµ-myc/pim2 and Eµ-myc/AKT tumors revealed early relapse
and shortened survival when a treatment of doxorubicin was
administered, and rapamycin treatment had little effect on any
of the tumors. However, the combination of rapamycin and
doxorubicin caused dramatic responses in the AKT-expressing
lymphomas but had no effect on pim2-expressing tumors. The
chemoresistance caused by AKT, but not by pim2, was there-
fore readily reversed by mTORC1 inhibition. Interestingly, both
pim2- and AKT-expressing lymphomas relied on cap-dependent
translation, and the rate-limiting factor for this translation is the
activation of the cap-binding protein by phosphorylation of its
inhibitor 4E-BP1, which can be further enhanced by direct eIF4E
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phosphorylation. The administration of silvestrol, an inhibitor of
eIF4E, was able to reverse pim2-mediated rapamycin resistance in
human lymphoma cells and in vivo (63).
In pre-B-cell acute lymphoblastic leukemia in children, chro-
mosomal translocations can lead to the fusion of the E2a and
Pbx1 genes. Dedera and co-workers generated a transgenic mouse
model that expresses the E2a-pbx1 oncogene under the control of
the immunoglobulin heavy chain enhancer Eµ. These mice devel-
oped lethal, high-grade T-cell lymphomas by 5 months of age (64).
However, the disruption of thymocyte differentiation and growth
control was not sufficient for malignant transformation, and addi-
tional oncogenes may be implicated in this process (64). The high
latency of the clonal tumors indicates that the E2a-pbx1 oncogene
is not sufficient for malignant transformation. An M-MuLV retro-
viral insertion strategy was designed to identify additional genes
that were able to decrease the latency of thymic lymphoma devel-
opment (65). Neonatal infection substantially reduced the survival
rate due to accelerated T-cell lymphoma development (81 versus
130 days). The pim1 gene was targeted by retroviral insertions in
48% of the accelerated lymphomas, whereas <5% of the lym-
phomas contained activated c-myc, and none contained activated
pim2. In the same study, cooperation between c-myc and pim1 was
demonstrated in double-transgenic mice. The characterization of
the developed tumors showed them to be monoclonal, provid-
ing some evidence that additional genetic events were required
for transformation. However, although the ability of E2a-Pbx1
to cooperate with Pim1 in lymphomagenesis appears to func-
tion analogously to the interaction between Pim1 and c-Myc, this
synergy does not appear to be as potent as the latter one (65).
Recently, attempts have been made to modify retroviral inser-
tion strategies in order to search for genes that might be impli-
cated in the later stages of tumor development. One approach
is the transplantation of primary tumors into syngenic recipi-
ent mice. By the propagation of tumors induced by M-MuLV in
Eµ-pim1 or H2K-myc transgenic mice, frat1 was identified as a
collaborating gene in later stages of lymphomagenesis (66). Cell
lines with high expression of Myc and Pim1 had an additional
growth advantage when infected with Frat1-expressing retrovirus
and transplanted. In a subsequent experiment, the authors exam-
ined the effect of enhanced Frat1 expression in transgenic mice
(Eµ-pp-frat1) (67). As expected, Frat1 expression did not pre-
dispose the animals to spontaneous tumor development but did
increase the susceptibility of these animals to M-MuLV-induced
T-cell lymphomagenesis. When the Eµ-pim1 transgene was simul-
taneously introduced to this mouse model, the incidence of spon-
taneously occurring lymphomas was significantly higher than in
Eµ-pim1 single-transgenic mice of the same genetic background.
These results demonstrated that frat1 and pim1 collaborate in
lymphomagenesis (67).
Knock-out-mice have also been successfully combined with
retroviral infection models to study the collaborators of tumor
suppressor genes. Mice lacking a functional p53 gene developed
tumors significantly faster after infection with M-MuLV than
uninfected p53−/−mice or virus-infected p53+/+ littermates (68).
However, the degree of synergy between M-MLuV and the p53
null genotype was weaker than the synergies between either of
these and the c-myc transgene. A similar phenotype range of T-cell
tumors was observed in all p53 genotype groups, including p53−/−
mice, which developed thymic lymphomas as the most common
of several neoplastic diseases. A lack of p53 was associated with
higher rates of metastasis and the rapid establishment of tumors in
tissue culture. An analysis of c-myc, pim1, and pal1 demonstrated
that these loci were occupied by proviruses at similar frequen-
cies in p53 wild-type and null mice. Therefore, virus-induced
tumors generally occur without the loss of p53, while the inac-
tivation of p53 in the germ line predisposes mice to tumors that
are phenotypically similar to the M-MuLV-induced ones.
Another example of the use of double-transgenic mouse mod-
els to study the function of Pim1 in T-cell development was estab-
lished by crossing a pim1 transgene into mice that are deficient
in either the cytokine or TCR signal transduction pathways (69).
β-selection is the process of differentiation and proliferation initi-
ated in thymocytes that is lacking in recombination-deficient SCID
or Rag-deficient mice, resulting in a differentiation block at the
CD4−8−25+44− stage of α/β T-cell development (70–72). When
these Rag-deficient mice were infected with M-MuLV, thymic lym-
phomas developed at a very high incidence and with an average
latency period of 150 days. These data indicated that the M-MuLV-
infected and transformed pro-T-cells of Rag-deficient mice induce
lymphomagenesis, compensating for the lack of a pre-TCR signal
in Rag-deficient mice (69).
Because the IL-7-IL-7R complex is critical in controlling the cel-
lularity of the pro-T-cell compartment, Eµ-pim1 transgenic mice
were crossed to γc-deficient and IL-7-deficient mice. The results
indicated that pim1 was capable of restoring thymus cellularity
to an appreciable extent and that pim1 could compensate for the
lack of cytokine signaling, allowing pim1 transgenic, γc-deficient
or IL-7-deficient thymocytes to expand. In the same study, the
question of whether the frequent proviral insertions into the pim1
locus of CD4+8+ tumors were casually involved in the differen-
tiation into pre-T-cell-like tumors was addressed by introducing
the Eµ-pim1 transgene into Rag-deficient mice. The thymocytes
of the transgenic Eµ-pim1;Rag−/− animals showed differentiation
and slow expansion from large CD4−8−CD25+ into small resting
large CD4+8+CD25− pre-T-cells; this pim1-mediated differenti-
ation was age-dependent. Strikingly, when the Eµ-pim1 transgene
was introduced into the CD3−/− background, in which most thy-
mocytes are blocked at the CD4−8−CD25+ stage, no further
differentiation or expansion of pim1 transgenic CD3γ-deficient
pro-T-cells was observed, regardless of age (69).
In summary, proviral tagging and bi-transgenic mouse mod-
els have allowed the identification of genes that are implicated
in T-cell development and the description of cooperating genes
implicated in the development of different hematological tumors.
Pim has emerged as a crucial player in both processes (Tables 4
and 5; Figure 1).
Pim TRANSGENIC MODELS AND CARCINOGENS
Generally, the spontaneous tumor rate in Pim1 transgenic mice
is low. As has been described above, only 10% of Eµ-pim1
mice develop spontaneous T-cell lymphoma after 240 days. These
tumor rates drastically increase after treatment with carcinogens.
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Table 4 | Proviral integration in the pim loci and cooperating oncogenes after M-MuLV infection of transgenic mice.
Transgenic model Integration site Phenotype and latency (non-infected versus infected with M-MuLV)
Eµ-pim1 c-myc (81%) T-cell lymphomas
N-myc (19%) From 10 to 92% penetrance
pal1 (93%) From 22 to 7–8 weeks average latency (22, 25, 73)
frat1 (17%) (transplanted infected tumors)
Pim1− /−a pim2 (25%) T-cell lymphomas with 100% penetrance
c-myc or N-myc (28%) From 14 to 18 weeks average latency (11)
Eµ-c-myc pim1 (31%) B-cell lymphomas
bmi1 (35%) From 80 to 100% incidence
pal1 (28%) From 18 to 7 weeks average latency (10)
bla1 (14%)
Eµ-c-myc; Pim1− /− pim2 (80%) B-cell lymphoma
No differences in penetrance (100%) or latency (50 days) (11)
Eµ-c-myc; Pim2− /− pim1 (40%) Mature B-cell lymphoma
No differences in penetrance or latency (30)
Eµ-c-myc; Pim1− /−;Pim2− /− pim3 (24%) Mature B-cell lymphoma
Tpl2 (18.4%) From 21 weeks of latency to 24 weeks of latency (30, 59)
cyclin D-2 (13%)
c-kit (8%)
Dkmi1 (5%)
Dkmi9 (8%)
Dkmi11 (5%)
Dkmi15 (10.5%)
Dkmi20 (8%)
Dkmi28 (10.5%)
Eµ-L-myc; Eµ-pim1b pal1/gfi1 (37–75%) T-cell lymphomas with 100% penetrance
Tiam1 (12%) From 14 to 8.5 weeks average latency (50, 73)
bla1 (8.5%)
CD2-myc pim1 (4–7.7%) Lymphoblastic thymic lymphomas
til1 (32%) From 3–33 to 100% penetrance
ahi1 (2.5%) From 4 to 1 months average latency (51–53)
Eµ-v-abl 40 c-myc (21%) From plastocytomas to disseminated lymphoma
N-myc (21%) From 60 to 100% penetrance
pim1+ c-myc or N-myc (14%) From 10 to 7 weeks average latency (60)
Eµ-bcl2 c-myc (26%) From pre-B-cell lymphoma and plastocytoma to clonal pre-B-, B-, and
immature T-lymphoma
pim1 (6%) From 3–15 to 100% penetrance
pim2 (23%) From up to 53 to 19 weeks average latency (61, 74)
Eµ-Bmi1 N or c-myc (39%) B- and T-cell lymphoma with 100% penetrance
pim1 or 2 (31%) From 18–25 to 9 weeks average latency (48)
Tet-o-BCL6; EµSR-tT a–c pim1 (21%) From splenic B-cell lymphomas to T- and B-cell lymphomas
From 6 to 45.3% penetrance
From 26 to 11.5 weeks average latency (57, 58)
E2a-pbx1 pim1 (48%) Diffuse high-grade T-cell lymphomas with 100% penetrance
pim2 (0%) From 18 to 11.5 weeks average latency (65)
c-myc or N-myc (5%)
(Continued)
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Table 4 | Continued
Transgenic model Integration site Phenotype and latency (non-infected versus infected with M-MuLV)
CD2-runx2 c-myc and/or N-myc (82%) Thymic lymphoma
pim1 (21%) From 6 to 100% penetrance
pal1 (39–44%) From 53 to 14 weeks (55)
Increased levels of Pim1 w/o proviral
integration in the pim-1 locus
Eµ-pp-frat1 c-myc (37–50%) From no tumors to 100% development of T-cell lymphoma between
11 and 14 weeks (67)N-myc (6%)
pim1/pim2 (23%)
gif1/pal1 (18%)
Rag2− /− pim1 (50%) From no tumors to 80% lymphomas with a latency of 21 weeks (69)
pim2 (0%)
p53− /− pim1 (25%) only in p53+ /− Thymomas with 100% penetrance
From 26 to 13 weeks average latency (68)
aIn this case, the comparison is carried out between pim1-expressing and infected pim-null mice.
bInfection with wild-type and sup-F M-MuLV.
cInfection with MOL4070LTR.
Breuer et al. showed that treatment with a single low dose of
N -ethyl-N -nitrosourea (ENU) increases the incidence of tumors
to 100% within 200 days. c-myc overexpression could be detected
in all of the ENU-induced lymphomas, underlining the synergistic
effects of both genes (23). Further studies also showed a high dose-
dependency of tumor incidence and c-myc overexpression to ENU
treatment (76). Due to these results, it was estimated that Eµ-pim1
transgenic mice were 25-fold more susceptible to ENU-induced
carcinogenesis than non-transgenic littermates (76).
The synergistic effect of c-myc and pim1 in tumor development
was also shown in methyl methanesulfonate (MMS)-treated AKR
mice, where MMS accelerated tumor development. These tumors
do not show K-ras mutations, but they do show integration in the
c-myc and pim-1 loci by endogenous murine leukemia virus, most
likely due to the insertion of proviral DNA (77). When AKR mice
were treated with N -methyl-N -nitrosourea (MNU), tumor devel-
opment started as early as 3 months of age, and pim1 and c-myc
gene rearrangements due to proviral integration were observed in
several of the resulting thymomas. Spontaneous tumors in AKR
mice (which usually develop at 6 month of age) are distinct, and
the development of thymomas that contain proviral integrations
at the pim1 locus in the MNU-treated AKR mice involves the coop-
eration between the chemical carcinogen and endogenous murine
leukemia virus (78).
Because the mortality in Pim1 mice associated with ENU expo-
sure was closely related to the onset of neoplastic development
(79), the Pim1 transgenic mouse models were considered optimal
to test carcinogens and to assay agents for the chemoprevention of
lymphomas.
McCormick and colleagues assessed the efficacy of N -(4-
hydroxypheny)-all-trans-retinamide (4-HPR) andα-difluorometh
ylornithine (DFMO) as chemopreventive agents in the Pim-1 lym-
phoma model system treated with ENU. Although DFMO had no
effect on lymphoma incidence, latency, or mortality, a high dose
of 4-HPR greatly reduced both lymphoma incidence and mortal-
ity at 20 weeks post-ENU administration; at 20 weeks post-ENU,
the incidence of lymphoma and the mortality rate of animals fed
with high dose of 4-HPR were half of those of the dietary control
cohorts. However, upon termination of the study (at 35 weeks),
the lymphoma incidence and mortality were similar across all
study groups, implying that the chemoprevention provided by
4-HPR only represents a delay rather than an inhibition of tumor
development (79).
Because Eµ-pim1 mice are 25-fold more susceptible to
ENU-induced lymphoma, this mouse model seemed to be
useful to test a variety of other carcinogens. For exam-
ple, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), a
potent mouse lymphomagen, and 2-amino-3-methylimidazo[4,5-
/]quinoline (IQ), a liver carcinogen that also causes lung tumors
and tumors of the forestomach in mice, were tested in Eµ-
pim1 mice. Both carcinogens were included into the stan-
dard diet at 0.03%. Whereas transgenic Eµ-pim1 mice are
highly susceptible to PhIP-induced lymphomagenesis, they do
not respond to the IQ treatment. PhIP increased the num-
ber of tumors and reduced the latency of tumor develop-
ment; surprisingly, this effect was strongest in female Eµ-Pim1
mice (80, 81).
A different study also tested four genotoxic procarcinogens in
the Eµ-Pim1 transgenic model: 2-acetylaminofluorene (AAF), n-
nitrosodiethylamine (NDEA), 1,2-dichloroethane (1,2-DCE), and
benzene (BEN). These compounds all require metabolic activa-
tion and, with the exception of benzene, are not mouse lym-
phomagens (82). Over the time course of 38 weeks, the com-
pounds were administered daily by oral gavage. Only a small,
but statistically significant, increase in the incidence of malig-
nant lymphomas was observed in the males treated with a
high dose of AAF, females treated with high and low doses
of NDEA, and females treated with a high dose of DCE (82).
www.frontiersin.org May 2014 | Volume 4 | Article 109 | 11
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aguirre et al. Pim proteins in mouse models
Table 5 | Contribution of Pim1 overexpression to tumorigenesis in double-transgenic mouse models.
Mouse model Single-transgenic phenotype Double-transgenic phenotype
E2a-Pbx1; H2K-pim1 E2a-Pbx1: 13% incidence lymphoma at 24 weeks
H2K-pim1: no tumors in 1 year
Lethargy, respiratory distress, and abdominal
distension due to aggressive lymphomas, 100%
incidence at 13 weeks (65)
Eµ-c-myc;Eµ-pim1 EµPim1: enlargement of the spleen Pre-B-cell leukemia in uterus; 100% incidence
(28)Monoclonal T-cell lymphoma; 10% incidence at 34 weeks of age
Eµ-c-myc: pre-B-cell lymphomas; 75% incidence latency between 10
and 53 weeks of age
Eµ-L-myc;Eµ-pim1 Eµ-pim1: enlargement of the spleen T-cell lymphomas; 80% incidence at 12 weeks
(49)Monoclonal T-cell lymphoma; 10% incidence at 34 weeks of age
Eµ-L-myc: T-, B-, and pre-B-lymphomas; 8% incidence at 53 weeks of age
Eµ-N-myc;Eµ-pim1 Eµ-pim1: enlargement of the spleen B- and pre-B-lymphomas; 95% incidence at
5 weeks of age (49)Monoclonal T-cell lymphoma; 10% incidence at 34 weeks of age
Eµ-N-myc: B- and pre-B-lymphomas; 50% incidence between 13 and
16 weeks of age
Lck-gfi-1; Eµ-pim1 Lck-gfi-1: developmental block of early T-cell development leading to a
loss of thymic cellularity. T-cell lymphomas; 15% incidence at
28.5 weeks of age
Thymus cellularity restored. T-cell lymphomas;
82% incidence at 16.2 weeks of age (50, 75)
Eµ-pim1: enlargement of the spleen
Monoclonal T-cell lymphoma; 10% incidence at 34 weeks of age
CD2-runx2;Eµ-pim1 CD2-Runx2: T-cell lymphomas; 23% incidence at 53 weeks T-cell lymphoma; 66% incidence at 36 weeks
(55)Eµ-Pim1: enlargement of the spleen
Monoclonal T-cell lymphoma; 10% incidence at 34 weeks of age
CD2-runx2;Eµ-pim1;
CD2-c-myc
CD2-Runx2: T-cell lymphomas; 23% incidence at 53 weeks T-cell lymphoma; 100% at 5 weeks (55)
Eµ-pim1: enlargement of the spleen
Monoclonal T-cell lymphoma; 10% incidence at 34 weeks of age
CD2-c-myc: T-cell lymphomas; 100% incidence at 7 weeks
Eµ-pim1; γc− /− Eµpim1: enlargement of the spleen Thymus cellularity restored (69)
Eµ-pim1;IL17− /− Monoclonal T-cell lymphoma; 10% incidence at 34 weeks of age
γc
− /− and IL17− /−: significant reduction in thymocyte number
Eµ-pim1;Eµ-pp-Frat1 Eµpim1: T-cell lymphoma; 12% incidence at 26 weeks of age T-cell lymphoma; 50% incidence at 26 weeks.
High levels of expression of c-myc (67)Eµ-pp-Frat1: no tumors at 26 weeks of age
Eµ-pim1;Rag3− /− Eµpim1: enlargement of the spleen Thymus cellularity restored in an age-dependent
manner in Rag3− /− but not CD3γ− /− mice (69)
Eµ-pim1; CD3γ− /− Monoclonal T-cell lymphoma; 10% incidence at 34 weeks of age
Rag3− /− and CD3γ− /−; differentiation block at the CD4−8−25+44−
stage of αβT-cell development
Eµ-c-myc;Eµ-pim2 Eµpim2: T-cell lymphoma; 40% incidence after 53 weeks Severe leukemia, some harboring simultaneous
T-cell lymphoma; 100% incidence at 3–4 weeks
of age (29)
Eµ-c-myc: Pre-B-cell lymphomas; 75% incidence and latency between
10 and 53 weeks of age
Eµ-Myc HPCs expressing
AKT, Pim2, or vector
inoculated into lethally
irradiated syngeneic
wild-type recipients
Eµ-Myc: HPCs with vector; pre-B-cell lymphomas with 20% incidence
at 14 weeks
Eµ-Myc; Arf− /− tumors responded to doxorubicin or rapamycin but
responded to the combination
Eµ-Myc HPCs with Pim2: pre-B-cell lymphomas
with 100% incidence at 10.7 weeks of age.
Resistant to doxorubicin, rapamycin, and
combination treatment
Eµ-Myc HPCs with AKT : pre-B-cell lymphomas
with 100% incidence at 12 weeks. Resistant to
doxorubicin and rapamycin but sensitive to
combination treatment (63)
(Continued)
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Table 5 | Continued
Mouse model Single-transgenic phenotype Double-transgenic phenotype
Eµ-Myc: Tsc2− /− HPCs
expressing Pim2 or vector
inoculated into lethally
irradiated, syngeneic
wild-type recipients
Eµ-Myc: Tsc2− /− tumors treated with rapamycin relapse-free up to
3 weeks
Eµ-Myc: Tsc2−/− with Pim2 tumors treated with
rapamycin resistant or relapsed free up to
2 weeks, treatment with silvestrol delayed
relapse to 2.7 weeks (63)
pim1;PSA61-Cre; pten+/− Prostate and bladder epithelium Hormone-induced high-grade mPIN lesions in
cooperation with pten loss; no cooperation in
aging-induced mPIN. Increased inflammation
surrounding target tissues leading to
pyelonephritis with 100% penetrance in
16-week-old mice (33)
One round of hormone treatment induced
high-grade bladder hyperplasia in cooperation
with pten loss
86% Penetrance in 16 weeks old mice (34)
Eμ-pp-frat1
Eμ-bcl2
Eμ-v-abl  40
E2a-pbx1
Eμ-bim1
C57BL6
Eμ-c-myc
Tet-o-BCL6;EμSR-tTa
CD2.runx2
CD2-myc
Eμ-pim1
Eμ-pim1; Eμ—L-myc
FIGURE 1 |Which genes and proviral insertion sites cooperate with
Pim1? In different mouse models, pim1 (green ellipse), pim2 (red ellipse),
c-myc (blue ellipse), N-myc (brown ellipse) and Pal1/gfl1 (purple ellipse) are
the more frequent proviral insertion sites in M-MuLV infection. The
cooperation between Pim1 and some of these other genes has also been
confirmed by bitransgenic mouse models (underlined and bold).
However, BEN, the only carcinogen known to be a lymphoma-
gen, did not increase the incidence of tumors significantly. The
authors here argued that the study time for BEN might have
been too short because other studies of BEN-induced lymphoma
detected tumors after 48 weeks in female mice and 54 weeks in
male mice.
The study presented by Kroese and colleagues tested two chem-
icals that target the lymphohematopoietic system, Benzo[a]pyrene
(B[a]P) and 12-O-tetradecanoylphorbol-13-acetate (TPA), in the
same Eµ-pim-1 mouse model. B[a]P, given three times a week
by oral gavage for 13 weeks at 4.3, 13, or 39 mg/kg body weight
resulted in a dose-dependent increase in lymphomas, with up to
a 90% incidence in Eµ-Pim1 mice during the observation period
of 40 weeks; in contrast, the non-transgenic mice did not develop
lymphomas. B[a]P also induced tumors of the forestomach within
this observation period, although at a lower incidence and with an
apparently equal effectiveness in the wild-type (83). However, in
this study, TPA did not induce lymphoma or other tumor types
in any tested genotype. The authors speculated that the negative
results for TPA were due to unresponsiveness to non-genotoxic
chemicals that only provide tumor-promoting activity (83).
Another study showed that mitomycin c does not act as a lym-
phomagenic agent in Eµ-pim1 mice (84). It was also shown that
Eµ-Pim1 mice were at least threefold more sensitive to fraction-
ated total body X-irradiation than non-transgenic control mice.
After X-irradiation, transgenic mice developed T-cell lymphomas
with high levels of c-myc in 75% of the tumors and a three to
fivefold increase in endogenous pim1 (85, 86). Lymphoma also
developed in the transgenic mice with a shorter latency than in
wild-type littermates. This assay showed that Eµ-Pim1 mice are
highly susceptible to X-ray-induced lymphoma and thus suscep-
tible to carcinogens that act directly to induce large chromosomal
deletions and rearrangements rather than point mutations (84).
Altogether, the Eµ-Pim1 mouse model is a highly sensitive
in vivo system for short-term carcinogen testing that is limited
to genotoxic carcinogens that induce lymphomagenesis through
large gene deletions and rearrangements.
Most carcinogenic assays elucidating pim kinase function were
carried out in Pim1 transgenic mice, but similarities can be
observed when using transgenic mice that overexpress human
Pim-3 in the liver. These mice do not develop HCC sponta-
neously, but when treated with DEN, Pim-3 transgenic mice
develop a significantly higher incidence of HCC than treated
wild-type mice. This might indicate that other Pim transgenic
mouse models are also suitable for short-term assays using
carcinogens (35).
The increased susceptibility of Pim mouse models to carcino-
gens is summarized in Table 6.
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Table 6 | Carcinogens strongly induce tumorigenesis in Pim mouse models.
Mouse model and
phenotype
Carcinogen: dose and
time of treatment
Carcinogen action Phenotype Increased levels of
oncogenes or K-ras
mutation
Eµ-pim1: 10%
mice developed
T-cell lymphoma,
at 34 weeks
ENU 200, 60, 15, 4.1, or
0.1 mg/kg, 15 days after
birth
Small alkyl DNA
adducts
T-cell lymphomas: latency of 17 weeks
for the highest dose and 34 weeks for
the lowest doses
Penetrance: 100–70% for the three
highest doses and 20% for 4–0.1 mg
7 kg dose
Enhanced expression of
c-myc without
rearrangement or
amplifications. Incidence
of mutations: 4.5% N-ras
mutations, 9% K-ras
mutations (23, 76)
ENU 50 mg/kg in
combination with
dietary administration
of 4-HPR, DFMO as
chemopreventive
agents
Small alkyl DNA
adducts
Infiltrative metastatic lymphomas.
Only 4-HPR induces a dose-related
delay in tumor progression
n.d. (79)
Diet of 0.03% PhiP for
7 months or 0.03% IQ
for 6 months
Carcinogenic or
mutagenic, respectively
Lymphoblastic lymphoma in 80% of
the females and 27% of the males,
28.5 weeks after treatment
n.d. (80, 81)
25 and 100 mg/kg AAF,
1 and 3 mg/kg NDEA,
100 and 300 mg/kg
1,2-DCE, and 50 and
100 mg/kg BEN
Genotoxic
procarcinogens
Pleomorphic, lymphocytic lymphomas,
and leukemias. Small but significant
increase in incidence of malignant
lymphomas in males treated with a
high dose of 2-AAF (3.4-fold), the
females treated with high and low
doses of NDEA (2.5-fold), and females
treated with a high dose of 1,2-DCE
(1.8-fold)
n.d. (82)
4.3, 13, or 39 mg/kg oral
administration of B[a]P
for 13 weeks and topical
administration of 10µg
TPA twice a week;
7 weeks interruption
and 35 weeks of 3µg
treatment. 220µg total
TPA dose/mouse
B[a]P requires
metabolism and
generates bulky DNA
adduct. TPA is a tumor
promoter
Multicentric lymphoma and T-cell
lymphomas with B[a]P
B[a]P dose-dependent induction of
lymphomas in males, starting at
25 days. Transgenic mice five time
more sensitive that wild-type
counterparts
75% Of mice had
increased c-myc levels,
and 12.5% of tumors
harbored K-ras mutations
(83)
Total body X-irradiation DNA strand breaks Dose-dependent incidence of T-cell
lymphomas: (4×1.5 Gy X-ray: 100%;
4×1.0 Gy X-ray: 90%; 4×0.5 Gy X-ray:
28%) 36 weeks after the last dose
75% Of mice had 5–20-
fold expression of c-myc,
and 16% mice have
increased pim-1 levels (85,
86)
Mitomycin c,
cumulative dose of
2.67–6.55 mg/kg
DNA cross-linking agent 11–30% Of females developed T-cell
lymphomas with no dose response
effect
n.d. (84)
alb-pim3 DEN 10 mg/kg Liver injury 81% Males developed hepatocellular
carcinoma after DEN treatment for
10 months (versus 41% of wild-type
mice)
n.d. (35)
(Continued)
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Table 6 | Continued
Mouse model and
phenotype
Carcinogen: dose and
time of treatment
Carcinogen action Phenotype Increased levels of
oncogenes or K-ras
mutation
AKR mice:
spontaneous
thymomas at
>24 weeks old.
MCF provirus
integration: 17%
pim1, 6.66%
c-myc
NMU 50 mg/kg,
4-week-old mice
Methylating agent; G-A
transition mutations
Thymomas between 12 and 24 weeks Ecotropic-like provirus
integration; 3.84% c-myc
and 9.33% pim-1. 24%
K-ras mutations (78)
MMS 120 mg/kg,
4-week-old mice
Methylating agent:
weak mutagen
Thymomas developed between 20 and
50 weeks in 100% of mice
MCF (mink cytopathic
focus-forming) provirus
integration 19.2% c-myc
and 4% pim-1; no
mutations in K-ras (77)
n.d., not determined.
CONCLUSION
Pim1 was discovered as a proviral insertion site in Moloney-
murine leukemia virus in T-cell lymphomas, and further studies
identified the other two family members, pim2 and pim3, as
alternative integration sites. This discovery prompted the devel-
opment of transgenic mouse models of pim1 to study its onco-
genic behavior. The Eµ-pim1 mouse model has been broadly
used to study oncogenic cooperation by infection with M-MuLV
and by crosses with other transgenic models; this model has
also been extensively used for carcinogen testing. pim-1 is a
weak oncogene that shows strong synergy with c-myc in lym-
phomas and prostate tumors. Double-transgenic mouse models
confirmed the cooperation between most of the complementa-
tion genes found by the infection of Pim transgenic mice with
M-MLuV.
The development of pim isoform-specific KO mice and double
and triple KO mice helped to understand the contribution of each
isoform to hematopoiesis as well as to sarcoma development and
progression.
However, there is still much work that must be performed to
fully understand the contributions of pim2 and pim3 to tumorige-
nesis and to elucidate the effects of the pim family on the complex
signaling network in which they are imbedded.
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